Organization | Chinese Society of Lung Cancer

Chinese Society of Lung Cancer Report issue

Foundation Phase 2 Phase 3 Phase 4

Founded: China

Organization Overview

First Clinical Trial

2007

NCT00492843

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 4 Trials (1)

ibandronate (boniva) (1 trial)

Drugs in Phase 3 Trials (3)

erlotinib (tarceva) (1 trial)

gefitinib (iressa) (2 trials)

thrombopoietin (1 trial)

Drugs in Phase 2 Trials (5)

carboplatin (paraplatin) (1 trial)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

pemetrexed (alimta) (1 trial)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Lung Neoplasms (Phase 4)

Neoplasm Metastasis (Phase 4)

Neoplasms (Phase 3)

Thoracic Neoplasms (Phase 3)

Thrombocytopenia (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 9